Relacorilant
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cushing Syndrome
Conditions
Cushing Syndrome
Trial Timeline
Nov 15, 2018 → Apr 15, 2024
NCT ID
NCT03697109About Relacorilant
Relacorilant is a phase 3 stage product being developed by Corcept Therapeutics for Cushing Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03697109. Target conditions include Cushing Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04308590 | Phase 3 | Completed |
| NCT06094725 | Phase 1 | Completed |
| NCT03697109 | Phase 3 | Completed |
| NCT03604198 | Phase 2 | Active |
Competing Products
20 competing products in Cushing Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD4017 and prednisolone + Placebo Oral Tablet and prednisolone | AstraZeneca | Phase 2 | 52 |
| Pasireotide with or without cabergoline | Novartis | Phase 2 | 52 |
| osilodrostat + LCI699 matching placebo | Novartis | Phase 3 | 77 |
| pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mg | Novartis | Phase 3 | 77 |
| LCI699 | Novartis | Phase 2 | 52 |
| Pasireotide sub-cutaneous | Novartis | Phase 3 | 77 |
| osilodrostat + osilodrostat Placebo | Novartis | Phase 3 | 77 |
| Osilodrostat | Novartis | Phase 2 | 52 |
| Pasireotide | Novartis | Phase 3 | 77 |
| Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + Metformin | Novartis | Approved | 85 |
| Pasireotide | Novartis | Phase 2 | 52 |
| SOM230 s.c. | Novartis | Phase 2 | 52 |
| Lu AG13909 | Lundbeck | Phase 2 | 49 |
| Osilodrostat | Recordati | Pre-clinical | 20 |
| Intervention/Treatment | Recordati | Approved | 82 |
| Pasireotide | Recordati | Pre-clinical | 20 |
| LCI699 | Recordati | Phase 2 | 49 |
| Pasireotide + Cabergoline + Pasireotide LAR | Recordati | Approved | 82 |
| Osilodrostat | Recordati | Pre-clinical | 20 |
| osilodrostat | Recordati | Phase 2 | 49 |